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Abstract. Magnetic nanoparticles have proven to be promising 
theranostic agents, namely tools for therapy and diagnosis. Among 
them, superparamagnetic iron oxide nanoparticles (SPIONs) highlight 
for their biocompatibility and reduced toxicity. Here, we describe the 
synthesis and characterization of SPIONs by co-precipitation of ferric 
and ferrous salts under mild conditions. These particles were able to 
accumulate in inflamed areas fact that was increased upon the 
application of an external magnetic field. Resonance magnetic 
imaging studies have shown their suitability as negative contrast 
agents for diagnosis. In addition, hybrid nanoparticles were obtained 
by incorporating the above described SPIONs into liposomes or 
nanoemulsions. The findings have confirmed the high potential of 
these systems for biomedical applications.              
 
Introduction 
       
      The impact of nanotechnology is strongly associated to the development of 
nanomaterials and nanoparticles (NPs) [1,2]. In particular, magnetic 
nanoparticles (MNs) present a number of advantages if compared to other  
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nanosystems. Their magnetic properties can be exploited for the targeting of 
drugs and as contrast agents. The duality that involves both therapy and 
diagnosis, all in one, or theranostic effect [3] has gained interest in the 
biomedical field, becoming an encouraging approach towards a personalized 
medicine. For that purpose, the design of nanosystems often requires the 
combination of one or several modifications of traditional NPs. It usually 
involves changes in their surface or their incorporation into other NPs 
conferring in this way also versatile, multifunctional, biocompatible and 
biodegradable properties [4,5]. 
 There is a great variety of materials that show magnetism in some extent 
depending on their atomic structure and temperature. The compounds with 
stable magnetic properties are classified into two main groups: ferromagnets, 
with permanent magnetism, and paramagnets, with magnetism that appears 
upon the application of an external magnetic field [6]. On the other hand, the 
size is a decisive aspect concerning to the functionality of the MNs.                     
A ferromagnet of macroscopic size contains numerous regions called 
magnetic domains in the demagnetized state. Within each domain all the 
atomic moments (represented as arrows in Fig 1) are aligned in one of the 
directions leading to spontaneous magnetization.  
   The direction of the magnetization, however, varies from domain to 
domain so as to minimize the magnetostatic energy. On a purely statistical 
basis, all available easy directions will be used equally in the material. 
Hence the particle as a whole will only show a net magnetization when 
submitted to an applied field [7]. A ferromagnet below a certain critical 
diameter (DCR) shows a single domain. Further reduction in size results in a 
superparamagnetic (DSPM) behavior meaning that magnetic properties are 
only present upon the application of an external magnetic field.   
 Among the several types of MNs, up to now, iron oxide nanoparticles 
(IONs) have proven to be the most promising MNs for theranostic 
applications mainly for their high imaging sensitivity, therapeutic efficacy, 
inherent biocompatibility and low cost [8]. This group comprises different 
chemical combinations of iron such as ferrites with a general formula 
MFe2O4 (M= Co, Ni, Zn, Mn), magnetite (Fe3O4), maghemite (γ-Fe2O3) or 
the non-stoichiometric mixture of the last two, with diameters comprised 
between 1 and 100 nm. This array of sizes supposes an additional advantage 
in the design of IONs with different magnetic behavior and consequently for 
a variety of applications. Therefore, below a certain diameter, DSPM, they are 
superparamagnetic being magnetized only in presence of a magnetic field. 
Superparamagnetic IONs (SPIONs) can be directed by an external magnet 
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towards a given target zone (Figure 2). Then, the application of a magnetic 
field moves the SPIONs toward the magnet and concentrates near its 
location. SPIONs revert to a non-magnetic state upon removal of the 
external magnet [9].  
 The application of a high-frequency alternating magnetic field can 
selectively heat SPIONs resulting in a hyperthermia effect that can be 
exploited for drug targeting. Therefore, their responsiveness to a magnetic 
field makes these particles suitable stimuli-sensitive systems as they can 
change their physical properties in response to an external stimulus and, in 
case of carrying drugs, these can be selectively delivered to the target site, 
minimizing any side effects [10]. 
 The magnetic properties SPIONs make them suitable candidates for 
molecular imaging (MI), a diagnostic approach that combines molecular 
biology and in vivo imaging performed in real time with the possibility of 
sequential and longitudinal monitoring. MI has the advantage over other 
diagnostic tools that allows high soft tissue contrast, spatial resolution and 
penetration depth for what it is considered one of the most powerful 
noninvasive imaging techniques in diagnostic [11,12,13]. In particular, 




Figure 2. Procedure for magnetically-guided drug targeting of nanoparticles. The 
enhanced permeability and retention effect facilitates the extravasation of the nanoparticles 
from the pores in leaky tumor blood vessel walls [6]. 
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resonance imaging (MRI) [14,15]. SPIONs improved the contrast-to-noise 
ratio in MRI by shortening the spin-spin T2 relaxation times of the water 
protons within the tissues or regions of interest, enhancing in this way the 
image contrast. 
 The versatility and functionality of SPIONs can be enhanced by 
modifications of their surface consisting mainly on coating the surface 
with ligands or by their inclusion into other nanoparticles giving hybrid 
nanosystems such as liposomes or nanoemulsions [16,17]. The 
combination of liposomes and SPIONs results in multifunctional 
magnetoliposomes (MLs) or all in one system that can also incorporate a 
variety of molecules. The first reference on MLs is found in a 1989 
publication by Kiwada [18]. These MLs had a size in the micrometer 
range, far too big for biological applications. From then, several 
procedures have been described resulting in nanometer-sized MLs [19,20]. 
Figure 3 shows a prototype of multifunctional or hybrid liposome (large 
unilamellar liposome, LUV), composed of phospholipids, with theranostic 
properties. Thus, encapsulated SPIONs in the inner core or embedded into 
the lipid bilayer provide a tool for magnetic targeting; the presence of                     




Figure 3. Prototype of a multifunctional large unilamellar magnetoliposome with the 
associated properties provided by each component. PEG: Polyethylene glycol;                       
RGD: Arginine (R)-Glycine (G)-Aspartic acid (D); Rho-B: Lissamine Rhodamine B 
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for biological targeting; drugs located depending on their hydrophilic or 
hydrophobic character as SPIONs in the aqueous compartment or among 
the lipid acyl-chains, respectively, make the systems appropriate for 
chemotherapy. On another hand, the presence of polymers (e.g. 
polyethylene glycol, PEG) on the outer leaflet of the vesicles, protect them 
from the opsonization and rapid uptake from the bloodstream once 
administered. Finally, fluorescent probes can be incorporated to the lipid 
bilayer for detection purposes. 
 Similarly, the incorporation of SPIONs into oil-in-water nanoemulsions 
results in magnetic nanoemulsions (MNEs). MNEs can include the same 
components as mentioned for liposomes and are particularly interesting as drug 
delivery systems of hydrophobic drugs. Both, MNEs and MLs are biodegradable 
and show low toxicity [22]. 
 
1. Synthesis and characterization of iron oxide nanoparticles 
 
 SPIONs were synthesized according to the method described by                       
Berger et al. [22]. Briefly, a mixture of Fe (OH)2 and Fe (OH)3 was obtained 




 in presence of strong alkali 
and under vigorous stirring. Subsequent fast aging of those hydroxides 
generates magnetite. The overall reaction is: 
 





 In order to provide colloidal stability to the particles and prevent their 
aggregation, they are usually coated with other nanoscale materials, resulting 
in the so named ferrofluids. Hydrophilic polymers such as dextran and its  
 























 1 Hydrodynamic diameter measured by dynamic light scattering 
 2 Polydispersity index. Its value varies from 0 for a monodisperse sample to 1 for a      
    polydisperse population. 
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derivatives, polyethylene glycol (PEG), chitosan (CHI) and alginate (ALG) 
are among the most used for the stabilization of naked magnetic 
nanoparticles [23]. We have studied the influence of the initial amount of 
CHI, ALG and PEG of different molecular weights in the stabilization of the 
magnetite. The optimal concentration of polymer needed for coating the NPs 
was calculated through adsorption isotherms and the amount coated was 
measured by thermogravimetry. 
 The ferrofluids were also characterized by measuring their size and size 
distribution by dynamic light scattering (DLS) and charge (  potential) with 
a Zetasizer Nano ZS90 (Malvern Instruments, UK). High-resolution TEM               
(HR-TEM, 2010F Jeol Microscope, Japan) indicated that the particle 
diameter was around 11 nm, value that was confirmed by X ray diffraction 
(XRD). Some of the above results are illustrated in Table 1 and Figure 4. 
 The magnetic properties of the ferrofluids under the influence of a magnetic 
field were measured with a superconducting quantum interference device 
(SQUID) magnetometer (Quantum design MPMS XL, San Diego, California, 
USA) at room temperature. All samples showed superparamagnetism without 
magnetic hysteresis at room temperature.  
 




 A lipid or lipid mixture of interest in chloroform/methanol (2:1, v/v) 
was introduced into a round bottom flask and the organic solvent was 
evaporated in a rotavapor under reduced pressure until the formation of a 
thin film. The dried mixture was then hydrated with an aqueous suspension 
of hydrophilic magnetic particles. In the case of hydrophobic SPIONs and 
hydrophobic drugs as indomethacin, they were added to the organic 
mixture and proceed as mentioned before. Up to now, the samples consist 
on a heterogeneous population of MLs. In order to obtain homogeneous 
samples, MLs were sonicated in an ultrasonic processor (Hielscher, 
Teltow, Germany) or submitted to extrusion cycles through a 200 nm 
polycarbonate filters (Extrude device, Avestin, Ottawa, Canada).                 
Ligand-targeted MLs with the arginine-glycine-aspartic acid motif (RGD) 
were also designed to study their ability to interact with cancer cells [24]. 
MLs were characterized as mentioned for SPIONs and additionally, the 
amount of lipid, encapsulated drug and SPIONs were measured as 
described in [9]. The average size of MLs was around 200 nm with low 
polydispersity (< 0.2). 
Magnetic nanoparticles: From diagnosis to therapy 9 
2.2. Magnetic nanoemulsions 
 
 The advantage of MNEs over MLs is their higher loading capacity of 
hydrophobic materials. Oil in water MNEs were prepared by mixing olive 
oil, cholesterol (CHOL) and the phospholipids 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine (DSPE-PEG) and 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC) dissolved in organic solvent. Hydrophobic 
SPIONs and indomethacin were also added to the organic phase. Then, the 
organic solvent was removed by rotary evaporation at 35 
o
C and the dried 
mixture was hydrated with water or buffered saline solution. The resulting 
crude emulsion was homogenized by spontaneous emulsification (low 
energy) or ultrasonication with an UP200 St ultrasonic processor 
(Hielscher, Teltow, Germany) (high energy) (Figure 5) [26,27]. NEs were 
characterized as described for MLs.  
 For internalization studies in cells, MLs and MNEs were labeled with 
the fluorescent probe 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-
N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rho-PE). In both 





Figure 5. Schematic representation of the magnetic NEs loading indomethacin and 
SPIONs obtained by high energy method (ultrasounds) or low energy method 
(spontaneous emulsification). On top components of the NEs [27]. 
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3. Magnetoliposomes accumulate in inflamed sites 
 
 The ability of MLs to reach inflamed areas was studied in a first 
assay by administering intravenously bare MLs to mice, namely MLs 
containing only phospholipids with encapsulated SPIONs [25]. 
Previously, sterile air pouches were produced by injecting air 
subcutaneously into the back of the mice. Then, animals were divided in 
four groups. In two of them, acute inflammation was induced by 
injecting 1.2 % carrageenan (phologen) to the pouch (inflammation 
groups). The injection in the other two groups (control groups) consisted 
on sterile saline. MLs were then injected i.v. to one of the two 
inflammation (I + MLs), and control groups (C + MLs). Mice were 
sacrificed 20 min after the injection.  
 The iron content in exudates (pouch), plasma and organs was 
analyzed by inductively coupled plasma atomic emission spectroscopy 
(ICP-AES, Perkin Elmer Optima 3200RL, Massachusetts, USA). Iron 
levels were higher in animals with inflammation that in control animals. 
After the administration of MLs to the control group, iron content 
increased similarly to the measured for animals with inflammation and 
MLs. There was no change in the concentration of iron in the liver after 
i.v. administration, whereas there was an increase in the spleen compared 
to the control group (Figure 6).  
 Iron biodistribution indicated that MLs accumulated mainly in the 
inflammation zone without the need of an external magnet to                      
potentiate the migration of MLs to the target site. A possible explanation 
to this fact is the enhanced permeability and retention effect as a 
consequence of the leaky vasculature of the tumor or in inflamed areas 
that allows the intratumoral accumulation of particles smaller than                 
200 nm [28]. 
 In a later study [9], a similar experiment was performed in which an 
external magnetic field induced a selective biodistribution of bare MLs to 
the inflamed area (Figure 7).  
 By this magnetically guided drug targeting approach, MLs 
accumulated at the site of inflammation (exudates) and simultaneously 
were removed from the blood. In addition, their content decreased in the 
liver and spleen. The increase in iron levels in exudates depended on the 
time of exposure of the external magnetic field (Table 2).  
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Figure 7. Experimental device to measure the effect of an external magnetic field on the 
biodistribution of MLs (left) after i.v. injection into mice (right). An inflammatory focus 
was introduced on their backs. Two ND2Fe12B disk magnets (25 x 10 mm, of 600 mT per 
side were place over the hole in the Plexiglas cages [9]. 
  





C 0.04 ± 0.04 4.04± 1.02 621±310 665±180 
I 0.26 ± 0.13 4.01± 1.27 712±224 836±278 
IN 0.33 ± 0.11 4.12± 1.07 873±99 1,446±390 
INM 0.56 ± 0.12 2.89± 0.42 674±64 1,264±35 
 
C: control, mice with back air pouch receiving sterile saline; I: inflammation control                    
group, animals with carrageenan-induced inflammation in the air pouch receiving 
saline; IN: as I but receiving MLs i.v; and INM as IN but under the effect of a magnet 
located just above the inflammatory pouch for 20 min (Figure 7) [9]. 
 
 TEM micrograph of the exudates showed the presence of intact MLs 20 min 
after the injection. This is a consequence of the size of the SPIONs (~ 12 nm) 
that is too large to passively cross the phospholipid bilayer. Iron release is only 
possible after the action of opsonins and cells of the mononuclear phagocyte 
system or other destabilizing agents. 
 
4. Ligand-targeted Magnetoliposomes 
 
 It is described that nanoparticles can be directed to a target site by 
functionalization of the external core. Insertion of peptides is one of the most 
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successful strategies [29]. For instance, the cyclic RGD peptide, bounded to the 
outer leaflet of the liposomal bilayer thorough a lipid-PEG-maleimido group, can 
bind vascular endothelial cells at inflammation sites [30]. Dubey et al. [31] 
indicated that cyclic RGD peptide anchored sterically stabilized liposomes 
bearing 5-FU were significantly more active against primary tumor and 
metastasis than the non-targeted sterically stabilized liposomes and free drug. 
Therefore cyclic RGD peptide anchored sterically stabilized liposomes hold 
potential of targeted cancer chemotherapeutics. Based on this premise, we 
designed an experiment aimed to study the targeting of RGD-MLs to integrin 
αVβ3 expressed in many cancer cells as the Hela cellular line. Bare MLs and 




Figure 8. Magnetoliposomes, MLs, composed of phosphatidylcholine (PC)/cholesterol 
(CHOL) (8:2 mol/mol) synthesized for internalization studies in Hela and 3T3 cells.    
PEG-MLs: pegilated MLs (long circulating) and RGD-MLs: functionalized MLs 
(biological targeting). The images correspond to confocal observations (Leika TCS-SP2, 
Heidelberg, Germany) after the incubation of MLs with Hela cells for 4 h. MLs were 
labeled with rhodamine-PE (red), the nucleus with membrane-permeable dye Hoeschst 
33342 (blue) and the cell membrane with cell membrane-impermeable Alexa Fluor                
488-conjugated wheat germ agglutinin (green). 
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 Previously to the cellular internalization studies, the cytotoxicity of 
naked SPIONs and MLs was analyzed in Hela and 3T3 (control) cellular 
lines by two typical assays, MTT that measures the metabolic activity in the 
mitochondria of viable cells and NR that gives information about the 
membrane integrity. MLs were viable at the concentrations studied [24]. 
 Unexpectedly, confocal microscopy and flow cytometry showed that 
bare MLs were internalized in higher extent than the MLs displaying the 
targeting moiety [24]. Apparently, cellular uptake of ligand-targeted MLs 
was inhibited by the PEG chains of the surface. To overcome this drawback, 
MLs surface should display PEG chains of different length, short to prevent 
the adsorption of proteins on the surface of the proteins and a long chain to 
favor the interaction with the cellular receptor.  
 
5. Magnetoliposomes as contrast agents for Magnetic 
Resonance Imaging 
 
 Agar phantoms with MLs or SPIONs were prepared to avoid particle 
aggregation during the application of the magnetic field. Then MRI 
measurements were performed on a 7.0 T BioSpec 70/30 horizontal animal 
scanner (Bruker BioSpin, Ettlingen, Germany). T1 (positive contrast) and T2 
(negative contrast) relaxometry maps as well as the relaxation rates r1 (1/T1) 
and r2 (1/T2) were obtained as described in [14]. The relaxivity for a MRI 
contrast agent calculated from equation 1 is described as the increase of the 
relaxation rate of the water (solvent) induced by 1 mmol.L
-1
 of the active 





 where i refers to 1 (r1) or 2 (r2), and CCA, to the iron concentration of the 
contrast agent (SPIONs). 
 Table 3 shows the relaxivity values for the SPIONs alone and incorporated 
into liposomes of different composition. r1 is poorly sensitive to SPIONs at 7 T 
due to the reduced susceptibility to dipolar contributions at high field, in addition 
to the presence of bulky surface groups hindering the surface accessibility of 
water to the magnetic cores. Contrarily, r2 values are bigger because transversal 
relaxivities are highly sensitive to the presence of substances around the 
magnetic core.   
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Table 3. r1, r2 and r2/r1 ratio of magnetic hydrophobic (O) and hydrophilic (H) 











O 0.96 74.5      78 
H 0.80 50.7     63 
O-DMPC 0.90 340    378 
H-DMPC 9.10 1282   140 
O-DMPC-CHOL 0.80 230   288 
O-DMPC-PS 0.80 798  1000 
O-DOPC 0.90 630  700 
H-DOPC 3.40 678  199 
O-DOPC-PS 0.90 995  1000 
 
 
      DMPC: 1,2-dimyristoyl-sn-glycero-3-phosphocholine; DOPC: 1,2-dioleoyl-sn- 
      glycero-3-phosphocholine; CHOL: cholesterol; PS: phosphatidylserine. 
 
 MLs composed of saturated (DMPC) or unsaturated phospholipids (DOPC), 
with or without CHOL or PS (negatively charged phospholipid) showed higher 
transverse reaction rates r2 compared to the values obtained for SPIONs alone as 
a consequence of the reduction of the diffusion coefficient of water near the 
nanoparticles. The coating of SPIONs with lipid bilayers provided a longer 
interaction between the water protons and the magnetic field at the surface of the 
magnetic core than in absence of coating. 
  
6. Magnetic nanoemulsions are suitable vehicles for 
hydrophobic drugs 
 
 NEs were chosen for their high payload, fact that favors the loading of large 
amounts of drugs. Therefore, multifunctional MNEs were prepared 
encapsulating indomethacin and SPIONs. Cytotoxicity studies were performed 
as described for MLs in Hela and 3T3 cellular lines. Then, the anti-inflammatory 
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activity of indomethacin loaded into MNEs, compared to the effect of free drug, 
was studied in a carrageenan-induced paw edema in rat model [26]. The height 
of the paw edema was measured at different times. Therefore, the study was 
performed with three groups of animals: A) carrageenan; B) carrageenan and 
indomethacin and, C) carrageenan and MNEs loaded with indomethacin. The 
peak of the edema was observed at 4 h for group A), and 6 h for the remaining 
two. The analysis of the area below the curve (Figure 9), with the                    
Turkey-Kramer statistical test, indicated the lack of differences between groups 
A and B or B and C, while significant differences (p<0.05) were noticed 




Figure 9. Top: viability of Hela and 3T3 cells after the incubation with magnetic-NEs for 
24 h. Bottom left: changes in paw edema induced by carrageenan in rats at different times, 
after administration of saline (control), free indomethacin (IND) (2mg kg-1) or 
indomethacin loaded MNEs (Nanoemulsion). Bottom right: area under the curve of the 
paw increase obtained from the data of the previous figure [26]. 
 
 Ulcers in the stomachs were observed only in the group that was 
administered with free drug, thus confirming protective role of the NEs in 
reducing the drug side effects. 
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7. Conclusion 
 
 Stable aqueous suspensions of superparamagnetic iron oxide nanoparticles 
stabilized with polyethylene glycol, chitosan or alginate (ferrofluids) were 
successfully prepared by a co-precipitation method under mild conditions. Their 
incorporation into liposomes gave also stable systems that showed ability to 
accumulate in inflamed areas, fact that increased upon the application of an 
external magnetic field. Magnetoliposomes presented enhanced negative 
transversal relaxivity (r2) compared to SPIONs, fact that indicates their 
suitability as negative contrast agents for magnetic resonance imaging. On 
another hand, magnetic nanoemulsions showed to be good vehicles for 
indomethacin with reduced side effects in comparison with the administration of 
the free drug. In summary, MLs and MNEs are good candidates as nanosystems 
for magnetic resonance imaging, for delivering hydrophobic drugs and can 
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